Akili, Inc. (NASDAQ:AKLI) Short Interest Down 34.7% in August

Akili, Inc. (NASDAQ:AKLI) was the target of a significant drop in short interest in August. As of August 31st, there was short interest totalling 120,100 shares, a drop of 34.7% from the August 15th total of 183,900 shares. Based on an average daily volume of 160,600 shares, the short-interest ratio is currently 0.7 days. Approximately 0.3% of the shares of the stock are sold short.

Akili Stock Down 28.7 %

Shares of NASDAQ:AKLI opened at $0.66 on Friday. The stock’s 50-day moving average price is $1.06 and its 200-day moving average price is $1.24. Akili has a 12-month low of $0.61 and a 12-month high of $4.31. The stock has a market capitalization of $51.56 million, a P/E ratio of -4.71 and a beta of 1.20. The company has a current ratio of 8.27, a quick ratio of 8.27 and a debt-to-equity ratio of 0.11.

Akili (NASDAQ:AKLI) last announced its quarterly earnings data on Thursday, August 10th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.02. Akili had a negative return on equity of 72.28% and a net margin of 940.71%. The firm had revenue of $0.11 million for the quarter. On average, equities analysts anticipate that Akili will post -0.85 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the stock. Tower Research Capital LLC TRC bought a new stake in shares of Akili in the third quarter worth about $32,000. SG Americas Securities LLC bought a new stake in shares of Akili in the first quarter worth about $33,000. CIBC Asset Management Inc bought a new stake in shares of Akili in the first quarter worth about $56,000. Geode Capital Management LLC grew its stake in shares of Akili by 55.0% in the fourth quarter. Geode Capital Management LLC now owns 38,504 shares of the company’s stock worth $43,000 after purchasing an additional 13,657 shares during the last quarter. Finally, Perpetual Ltd bought a new stake in shares of Akili in the first quarter worth about $124,000. 53.12% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Separately, Credit Suisse Group restated an “outperform” rating and set a $4.00 price target on shares of Akili in a research report on Friday, August 11th.

Akili Company Profile

Akili, Inc, a digital medicine company, develops cognitive treatments through game-changing technologies. The company provides EndeavorRx, a computer-based testing for cognitive dysfunction across several neurology and psychiatry indications, including attention-deficit hyperactivity disorder, depressive disorder, autism spectrum disorder, multiple sclerosis, and other neuroinflammatory diseases.